
Gleevec® (imatinib mesylate)

Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML)


CML: Linked to a Single Molecular Abnormality



The Philadelphia (Ph) Chromosome: t(9;22) Translocation

Hematopoiesis


http://www.biocarta.com/pathfiles/h_stemPathway.asp



BIOCARTA

IL3 Signaling Pathway http://www.biocarta.com/pathfiles/h_il3Pathway.asp


BIOCARTA





BCR-Abl Stimulates Cellular Proliferation and Inhibits Apoptosis

http://www.biocarta.com/pathfiles/h_gleevecpathway.asp



CML: a Progressive and Fatal Disease

Chronic phase	Advanced phases			
	Accelerated phase	Blast crisis		
Median duration 5–6 years	Median duration 6–9 months	Median survival 3–6 months		

CML: Its Cause and Management

- The Ph chromosome generates the Bcr-Abl tyrosine kinase—the molecular cause of CML
 - Constitutive activation leads to malignant transformation

Eliminating the Ph chromosome—a primary goal of therapy

- Complete cytogenetic response (0% Ph+ cells)
- Major cytogenetic response (≤35% Ph+ cells)
- Patients who achieved a complete/major cytogenetic response with SCT or IFN-α had prolonged survival vs patients without such a response
- Longer follow-up required to determine survival benefit of Gleevec[®]



Gleevec®: Pharmacokinetics

- Rapidly and completely absorbed after oral administration
- Terminal half-life (t_{1/2}) of Gleevec ≈18 h and of active metabolite ≈40 h, allowing convenient once-daily oral dosing
- 81% of Gleevec eliminated within 7 days
- Metabolized in the liver primarily by the cytochrome P₄₅₀ enzyme CYP3A4
 - In vitro competitive inhibitor of CYP3A4, CYP2C9, and CYP2D6
- Potential drug interactions between Gleevec and other substrates, inhibitors, or inducers of these enzymes

Phase I Study: Gleevec[®] Achieves Hematologic and Cytogenetic Responses

	Chronic Phase IFN-α Failure 300–1000mg/day (n=54)	Blast Crisis, Myeloid 300–1000mg/day (n=38)
Hematologic response	100%	55%
Complete	98%	11%
Cytogenetic response		
Major	31%	11%
Complete	13%	8%

Typically 4 weeks to achieve CHR, 2 to 10 months to achieve MCR
A maximal tolerated dose (MTD) was not reached (up to 1000mg/day)

Druker BJ et al. *N Engl J Med.* 2001;344:1031-1037. Druker BJ et al. *N Engl J Med.* 2001;344:1038-1042.

Phase II Results: Highest Response Rates in Chronic Phase

	Study 0110 Chronic Phase IFN-α Failure* (N=454)	Study 0109 Accelerated Phase* (N=181)	Study 0102 Blast Crisis* (N=229)
Hematologic response	93%	69%	31%
Complete response	93%	37%	7%
No evidence of leukemia		12%	5%
Return to chronic phase		20%	19%
Major cytogenetic response	53%	19%	7%
Complete response	32%	13%	1.5%

*Chronic phase: 400mg/day; advanced phases: 400mg/day or 600mg/day. Dose escalation permitted in all trials.

Gleevec® (imatinib mesylate) Prescribing Information.

For important safety information, please see slide 3 or full Prescribing Information.


IRIS Study: Reevaluating First-Line CML Therapy

- Gleevec[®] versus IFN- α + ara-C (Study 106)
- Rationale for first-line use of Gleevec
 - High response rate in patients failing IFN-α
 - Higher response rates in earlier phases
- Phase III, multinational, randomized, open-label
- Inclusion criteria: newly diagnosed chronic phase CML patients
- Primary objective—determine time to progression, defined as:
 - Increasing WBC count
 - Loss of CHR or MCR
 - Accelerated phase or blast crisis
 - Death

Secondary objectives—determine rate and duration of CHR and MCR; overall survival; safety; molecular response; quality of life (QoL) using FACT-BRM

IRIS: The Largest Phase III CML Study to Date

1106 patients enrolled from June 2000 to January 2001




S = screening.

R = randomization.


*Independent Data Monitoring Board recommended protocol amendment.

Longer Time to Progression With Gleevec®*




Higher Cytogenetic Response Rates With Gleevec^{®*}

Major Cytogenetic Response[†]



Complete Cytogenetic Response[‡]




*IRIS Study; n=553 in each arm. [†]≤35% Ph+ cells.

[‡]0% Ph+ cells.

For important safety information, please see slide 3 or full Prescribing Information.

P<0.001. Confirmed responses shown. Unconfirmed MCR—Gleevec: 83%; IFN-α + ara-C: 20%. Unconfirmed CCR—Gleevec: 68%; IFN-α + ara-C: 7%.

Early Responses in More Patients With Gleevec^{®*}



*IRIS Study.

For important safety information, please see slide 3 or full Prescribing Information.

More Patients Remain on Gleevec[®] Therapy

	Gleevec n=553	IFN-α + ara-C n=553
All Crossovers	1% (n=7)	39% (n=218)
Intolerance	<1%	23%
No CHR at 6 months	0%	7%
Increasing WBC count	<1%	5%
Loss of CHR	0%	4%
Loss of MCR	<1%	<1%
All Discontinuations	9% (n=51)	31% (n=170)
Withdrawal of consent	2%	13%
Adverse events	2%	6%
Progression to accelerated phase or blast crisis	1.5%	5%
All other causes	3.5%	7%
Remained on originally assigned treatment	90% (n=495)	30% (n=165)

Most Non-Hematologic Adverse Events Less Common With Gleevec^{®*}

Event	All Grades (%)		Grades 3/4 (%)	
	Gleevec n=551 [†]	IFN-α + ara-C n=533 [†]	Gleevec n=551 [†]	IFN-α + ara-C n=533 [†]
Superficial edema	53	9	<1	<1
Nausea	43	61	<1	5
Muscle cramps	35	10	1	<1
Musculoskeletal pain	34	41	3	8
Rash	32	25	2	2
Fatigue	31	65	1	24
Diarrhea	30	41	1	3
Headache	29	42	<1	3
Joint pain	27	38	2	7

*IRIS study; most common adverse events, listed by incidence with Gleevec (≥25%, regardless of causality). †All patients who received at least 1 dose of study drug.

Fewer Hematologic Adverse Events With Gleevec®*


	Gleevec (%) (n=551) [†]		IFN- _α + ara-C (%) (n=533) [†]	
	Grade 3	Grade 4	Grade 3	Grade 4
Neutropenia	11	2	20	4
Thrombocytopenia	7	<1	16	<1
Anemia	3	<1	4	<1

*IRIS Study. †All patients who received at least 1 dose of study drug.

Massive Protein Kinase Database

- Abbott Labs Publishes Massive Protein Kinase Dataset, New Statistical Method to Analyze Kinome
- March 11, 2011
- By Adam Bonislawski
- Scientists from Abbott Laboratories' pharmaceutical-discovery division have released kinomics screening data about how 3,800 different inhibitors affect 172 protein kinases.
- In a study published last month in the online edition of *Nature Chemical Biology*, the researchers showed how they tried to group these kinases based on both sequence and pharmacological relationships and by their interactions with various inhibitor chemoty

The genetic paradigm validated: -a dramatic reduction in the mortality from CML since 2001



The Genetic Basis for Cancer Therapeutics | William R. Sellers | November 27th*, 2012 | Business Use Only

Ga Journal Statistics

Gleevec®—CML Indications

Gleevec is indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). Follow-up is limited. Gleevec is also indicated for the treatment of patients with Ph+ CML in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. Gleevec is also indicated for the treatment of pediatric patients with Ph+ CML whose disease has recurred after stem cell transplant or who are resistant to interferon alpha therapy. There are no controlled trials demonstrating a clinical benefit, such as improvement in diseaserelated symptoms or increased survival, in patients with CML in blast crisis, accelerated phase, or chronic phase after failure of interferonalpha therapy.

Gleevec®—Important Considerations

- Use of Gleevec is contraindicated in patients with hypersensitivity to imatinib or to any other component of Gleevec
- Women of childbearing potential should be advised to avoid becoming pregnant
- Gleevec is often associated with edema and occasionally serious fluid retention*; GI irritation (and should be taken with food and a large glass of water to minimize this problem); anemia, neutropenia, thrombocytopenia, or occasionally severe hepatotoxicity or hemorrhage
- Gleevec is metabolized by the CYP3A4 isoenzyme and is an inhibitor of CYP3A4, CYP2D6, and CYP2C9. Please see full Prescribing Information for potential drug interactions


*Patients should be weighed and monitored regularly for signs and symptoms of edema, which can be serious or life threatening.

Gleevec®: Evolving First-Line CML Therapy

Gleevec surpasses IFN-α + ara-C by the following parameters measured in the IRIS study:

- Progression-free survival
- Complete cytogenetic response
- Major cytogenetic response
- Complete hematologic response
- Mild to moderate safety and tolerability profile

NCCN* CML Guidelines for Monitoring Response to Gleevec®



www.nccn.org/physician_gls/index.html

Optimal Dosing for Optimal Results

- Recommended starting doses of Gleevec[®]
 - Chronic phase: 400mg once daily
 - Advanced phases: 600mg once daily
- Monitor responses every 3–6 months
- Consider dose escalation (400mg to 600mg in chronic phase, 600mg to 800mg in advanced phases) in absence of severe adverse reactions or severe hematologic abnormalities for any of the following:
 - Failure to achieve a CHR after at least 3 months
 - Failure to achieve a cytogenetic response after 6–12 months
 - Loss of a previously achieved hematologic or cytogenetic response
 - Disease progression (at any time)


Dose escalation when appropriate may overcome resistance

Gleevec[®] Has Advanced the Treatment of Ph+ CML

- Therapy specifically designed to target the molecular cause of CML (Bcr-Abl)
- High rates of cytogenetic and hematologic response in all phases of disease
- Significant delay in time to disease progression for patients in chronic phase
- Mild to moderate side-effect profile
- Convenient, once-daily, oral dosing*
- Evolving first-line therapy for CML


For important safety information, please see slide 3 or full Prescribing Information.

Most Oncogenes are Not Kinases



Higher Dose: Longer Time to Disease Progression

Study 0109 (accelerated phase)



Some adverse events appear to be dose related.